Clinical Trials Browser

NCT07518173 2026-04-08

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

596 enrolled

Breast

HER2-positive Breast Cancer

NCT03975647 2026-03-30

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Phase 3 Active not recruiting

466 enrolled 17 charts

Breast

HER2-positive Breast Cancer

NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Phase 3 Recruiting

544 enrolled

Breast

HER2-positive Breast Cancer

NCT07377643 2026-02-25

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Phase 3 Recruiting

540 enrolled

Breast

HER2-positive Breast Cancer

NCT06830889 2026-01-22

A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

Phase 3 Recruiting

1,450 enrolled

Breast

HER2-positive Breast Cancer

NCT03588091 2025-08-22

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Phase 3 Completed

355 enrolled

Breast

HER2-positive Breast Cancer

NCT06316531 2025-08-19

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Phase 3 Active not recruiting

274 enrolled

Breast

HER2-positive Breast Cancer

NCT05705401 2025-08-03

HERO

Phase 3 Recruiting

1,300 enrolled

Breast

HER2-positive Breast Cancer

NCT06992882 2025-07-18

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

Phase 3 Recruiting

2,306 enrolled

Breast

HER2-positive Breast Cancer

NCT06968585 2025-05-13

A166

Phase 3 Active not recruiting

365 enrolled

Breast

HER2-positive Breast Cancer

NCT04957212 2024-07-26

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Phase 3 Completed

214 enrolled 16 charts

Breast

HER2-positive Breast Cancer

NCT06313086 2024-05-10

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Phase 3 Recruiting

442 enrolled

Breast

HER2-positive Breast Cancer

NCT06107790 2023-10-30

Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer

Phase 3 Completed

570 enrolled

Breast

HER2-positive Breast Cancer

NCT05985187 2023-08-14

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Phase 3 Unknown

412 enrolled

Breast

HER2-positive Breast Cancer

NCT05720026 2023-02-09

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

Phase 3 Unknown

560 enrolled

Breast

HER2-positive Breast Cancer

NCT05698186 2023-01-26

Thero2-01S22 in HER2-positive Breast Cancer

Phase 3 Not yet recruiting

320 enrolled

Breast

HER2-positive Breast Cancer

NCT05388500 2022-05-27

PHARE-C

Phase 3 Not yet recruiting

800 enrolled

Breast

HER2-positive Breast Cancer